NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer
Authors:
- Viktoria Florentine KoehlerVKViktoria Florentine Koehler
- Josefine AchterfeldJAJosefine Achterfeld
- Natalie SandnerNSNatalie Sandner
- Christine KochCKChristine Koch
- Jonas Paul WiegmannJWJonas Paul Wiegmann
- Philipp IvanyiPhilipp Ivanyi
- Lukas KäsmannLukas Käsmann
- Renate PuschRPRenate Pusch
- Dominik WolfDWDominik Wolf
- Mihaela ChiricaMCMihaela Chirica
- Thomas KnöselTKThomas Knösel
- Melanie-Christin DemesMDMelanie-Christin Demes
Open Access
- 7 August 2023
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (15) , 14035-14043
Abstract
Purpose: Pathogenic fusion events involving neurotrophic receptor tyrosine kinase (NTRK) have been described in ~ 2% of differentiated thyroid cancer (DTC). The selective tropomyosin receptor kinase (TRK) inhibitors entrectinib and larotrectinib have been approved in a tumor agnostic manner based on phase 1/2 clinical trials. In a real-world setting at five referral centers, we aimed to describe the prevalence of NTRK gene fusions and the efficacy and safety of TRK inhibitor treatment for non-medullary, advanced thyroid cancer (TC). Methods: A total of 184 TC patients with testing for NTRK gene fusions were included. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan–Meier method in six patients with NTRK fusion-positive TC who underwent TRK inhibitor therapy. Results: 8/184 (4%) patients harbored NTRK gene fusions. Six patients with radioiodine (RAI)-refractory TC harboring NTRK1 (n = 4) and NTRK3 (n = 2) gene fusions were treated with larotrectinib. Five patients (83%) had received ≥ 1 prior systemic therapy and one patient did not receive prior systemic therapy. All patients had morphologically progressive disease before treatment initiation. Objective response rate was 83%, including two complete remissions. Median PFS from start of TRK inhibitor treatment was 23 months (95% confidence interval [CI], 0–57.4) and median OS was not reached (NR) (95% CI, NR). Adverse events were of grade 1–3. Conclusion: The prevalence of NTRK gene fusions in our cohort of RAI-refractory TC is slightly higher than reported for all TC patients. Larotrectinib is an effective treatment option in the majority of NTRK gene fusion-positive advanced TC patients after prior systemic treatment and has a favorable safety profile.Keywords
Funding Information
- Munich Clinician Scientist Program Track FöFoLe+, medical faculty of the LMU Munich (Reg.-Nr. 044)
- Universitätsklinik München
This publication has 22 references indexed in Scilit:
- Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assaysGenes, Chromosomes and Cancer, 2019
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfallsLaboratory Investigation, 2019
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and ChildrenNew England Journal of Medicine, 2018
- Genetic landscape of papillary thyroid carcinoma in the Chinese populationThe Journal of Pathology, 2017
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid TumorsCancer Discovery, 2017
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Integrated Genomic Characterization of Papillary Thyroid CarcinomaCell, 2014
- The landscape of kinase fusions in cancerNature Communications, 2014
- Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancersJournal of Clinical Investigation, 2013
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010